Israeli company Atox Bio Ltd. has reported a successful clinical trial of its AB103 treatment for Necrotizing Soft-Tissue Infection (NSTI). Financial magazine Globes reports that due to the successful trial, that has shown that the drug was both effective and safe, the company has begun raising millions of dollars. NSTI is a life-threatening bacterial infection with significant morbidity and high mortality rate.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts

EU Awards $5M To Greenhouse Solar Panel Project
February 07, 2023

Israel Builds Super-Advanced Children’s Hospital
February 07, 2023

Two Thirds Of Hi-Tech Workers In Israel Are Men, Study Finds
February 06, 2023

Ancient Crop Is Gene-Edited For Modern Farms
February 06, 2023
Facebook comments